NEWSROOM
News & Stories
Newsroom
Press Releases
Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendiaโs MammaPrint Low Risk Result Can Safely Forgo Chemotherapy
MammaPrint is the only FDA-cleared gene expression test to identify early breast cancer tumors with an Ultra-Low risk that can safely avoid chemotherapy, with a 99% breast cancer specific survival (BCSS) and 97% distant metastasis Read More
Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium
Demonstrates the ongoing impact of its 10,000-patient FLEX trial to fuel breast cancer research and produce practice-changing results All six presentations will emphasize how MammaPrintยฎ and BluePrintยฎ empower personalized, proactive treatment decisions with test results Read More
Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer
The LESS study will evaluate reduced endocrine therapy for HR+/HER2- patients with MammaPrintยฎ Ultra Low tumors to improve quality of life without compromising outcomes Study strengthens Agendiaโs growing global footprint in breast cancer to inform Read More